Randomized, Multi-center Phase II Study to Evaluate the Efficacy and Safety of AHB-137 in HBeAg-negative CHB Subjects Under Stable Nucleos(t)Ide Analogue (NA) Treatment
Latest Information Update: 22 Nov 2026
At a glance
- Drugs AHB 137 (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors AusperBio
Most Recent Events
- 05 Nov 2026 According to an AusperBio media release,data from this trial will be presented at The Liver Meeting 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 5 to 9 in Denver, Colorado.
- 15 Sep 2026 Status changed from active, no longer recruiting to completed.
- 07 May 2026 Planned End Date changed from 30 Jun 2026 to 1 Oct 2026.